PMID- 24085111
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20131024
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 32
IP  - 6
DP  - 2013 Dec
TI  - Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for 
      the immunotherapy of advanced hepatocellular carcinoma.
PG  - 1366-72
LID - 10.3892/ijmm.2013.1510 [doi]
AB  - NY‑ESO‑1 is one of the most immunogenic cancer-testis (CT) antigens. Cancer 
      vaccine trials based on NY‑ESO‑1 are currently ongoing. Dendritic cells (DCs) are 
      the most potent antigen-presenting cells. The immune functions of DCs in a number 
      of tumors have been identified; however, the potential therapeutic value of DCs 
      pulsed with NY‑ESO‑1 in hepatocellular carcinoma (HCC) has not been extensively 
      investigated. The objectives of the present study were to evaluate T cell 
      response following stimulation with DCs pulsed with the recombinant NY‑ESO‑1 
      protein (rESO) and to establish a correlation between NY‑ESO‑1 expression and 
      clinicopathological features in HCC patients. DCs were generated with 
      granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-4 
      (IL‑4) from human peripheral blood mononuclear cells. A mixed T cell reaction 
      with DCs loaded with recombinant NY‑ESO‑1 protein (rESO-DCs) was evaluated by MTT 
      assay. T cell responses against HCC cell lines were analyzed by measuring lactate 
      dehydrogenase (LDH) activity. The protein levels of NY‑ESO‑1 were detected by 
      immunohistochemistry (IHC) in a tissue microarray (TMA) containing 190 HCC 
      samples. NY‑ESO‑1 transcript abundance was determined by reverse 
      transcriptase-polymerase chain reaction (RT-PCR) in 54 out of the 190 HCC 
      samples. The results revealed that mature DCs were induced and that rESO‑DCs 
      significantly stimulated T cell proliferation. The specific lysis of T cells 
      stimulated with rESO‑DCs was significantly higher in the NY‑ESO‑1-positive HCC 
      cells compared with the NY‑ESO‑1-negative cells and the other controls (p<0.01). 
      NY‑ESO‑1 was expressed in 15.8% (30/190)of the HCC samples, as shown by IHC and 
      in 24.1% (13/54) of the samples, as shown by RT-PCR. The frequency of NY‑ESO‑1 
      expression was significantly higher in HCC patients with portal vein tumor 
      thrombosis (24.6%) compared with those without thrombosis (11.2%, p=0.013). Our 
      data suggest that DCs loaded with NY‑ESO‑1 protein stimulate antigen-specific 
      T cell responses against HCC cells in vitro. NY‑ESO‑1 may thus be used as a 
      potential target for immunotherapy in advanced HCC.
FAU - Chen, Yuqing
AU  - Chen Y
AD  - Department of Pathology, Fujian Medical University, Fuzhou, Fujian 350004 
      P.R. China.
FAU - Huang, Aimin
AU  - Huang A
FAU - Gao, Meiqin
AU  - Gao M
FAU - Yan, Yongqin
AU  - Yan Y
FAU - Zhang, Wenmin
AU  - Zhang W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130927
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CTAG1B protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/*genetics/metabolism
MH  - Carcinoma, Hepatocellular/genetics/immunology/*pathology/*therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*metabolism
MH  - Female
MH  - Flow Cytometry
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Immunotherapy
MH  - Liver Neoplasms/genetics/immunology/*pathology/*therapy
MH  - Male
MH  - Membrane Proteins/*genetics/metabolism
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - RNA, Messenger/genetics/metabolism
MH  - T-Lymphocytes/cytology
MH  - Young Adult
EDAT- 2013/10/03 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/10/03 06:00
PHST- 2013/06/20 00:00 [received]
PHST- 2013/09/17 00:00 [accepted]
PHST- 2013/10/03 06:00 [entrez]
PHST- 2013/10/03 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 10.3892/ijmm.2013.1510 [doi]
PST - ppublish
SO  - Int J Mol Med. 2013 Dec;32(6):1366-72. doi: 10.3892/ijmm.2013.1510. Epub 2013 Sep 
      27.